

Preparation of a sustained delivery system of pilocarpine hydrochloride from poly(lactic- co-glycolic acid)/poly(lactic acid) for subconjunctival administration

Abdulrazaq Almiahi

31 August 2011

This research project is submitted in part fulfilment of the
requirements for the MSc in Drug Delivery degree,
University of London

Department of Pharmaceutics
School of Pharmacy
University of London

Abstract

Glaucoma is a progressive optic neuropathy characterized most commonly by elevated intraocular pressure (IOP). It is estimated that 67 million people have glaucoma worldwide, and the disease is considered to be the second cause of blindness. Being a progressive disease makes it very important for the patient to always have the IOP under control by maintaining the effective concentration of glaucoma drugs at the site of action (aqueous humor). The presence of many protective barriers around the eye makes it difficult for drug to reach to the aqueous humor in sufficient amount, especially for hydrophilic molecules which is the case of most anti-glaucoma drugs. The bad bioavailability of anti-glaucoma medicines means that drugs should be taken several times a day to ensure having the sufficient effective concentration at the site of action. Poor patient compliance arises due to inability of many patients to stick to the daily dosage regimen, thus progression of disease occurs. In this study a sustained release preparation for the delivery of pilocarpine hydrochloride for a relatively long period of time (more than three months, thus decreasing to a large extent the dosing frequency) was successfully fabricated using PLGA/PLA polymers alone or blended together, and different types of the polymer were used with different drug to polymer ratio to look for a preparation that gives best drug loading and release profile. A blend of PLGA (of 75:25 lactide to glycolide ratio) and PLA showed the most favourable drug loading and sustained release features, it was able to deliver 623 μg for about 3.5 months. By application of this preparation to the subconjunctival space, a potential may be obtained for overcoming the problems of poor bioavailability and patient compliance. Pilocarpine hydrochloride is used as a model drug for glaucoma medications, the drug is hydrophilic thus it gives a good idea about how glaucoma drugs can be made as polymeric sustained release preparations.